The global attention deficit hyperactivity disorder therapeutics market size to reach USD 17.5 billion by 2025 from USD 27.1 billion in 2020. The market is growing at a CAGR of 9.09% during the forecast period.
Attention deficit hyperactivity is a neurodevelopmental disorder that damages and envelops symptoms of impulsivity and hyperactivity. Treating and controlling the disease with the help of technology defines neurobehavioral because the way the brain affects learning, behavior, and emotion.
MARKET DRIVERS
The growing incidence of Attention deficit hyperactivity disorder across the world is fundamentally driving the market growth.
The causes of ADHD are still indistinct, although genetic presence is observed in many cases. As per the data given by the center for Disease Control and Prevention (CDC) in 2016, around 6.1 million individuals, including 388,000 children aged 2–5 years, 4 million 6–11 years, and 3 million 12–17 years, were diagnosed with ADHD in the U.S. besides, boys are more likely to be diagnosed than girls.
The frequency of ADHD is rising at a higher rate, which drives the global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. The ADHD therapeutics market is mostly driven by the rough impact of unstable lifestyles and additives in children's diet, increasing incidence of ADHD within the 4 to 17 year age group. Moreover, increasing awareness concerning syndrome among physicians and patients, and opinion-based due to the lack of regular diagnostic tests is anticipated to fuel revenue growth of the worldwide ADHD market in the coming future.
Additionally, increasing advancements in the medical field, a growing number of research in neurosciences, and raising awareness about mental illness among people are fuelling the market growth to a considerable extent. Furthermore, expanding the focus of biotechnology & pharmaceutical companies into developing the innovative therapeutics for ADHD drives the development of the global ADHD therapeutics market.
MARKET CHALLENGES
The high cost of the ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of the global ADHD therapeutics market.
All the side effects associated with ADHD drugs affect the lives of the patients, which will hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period. Problems like allergic reactions to medicine, medical conditions like coronary artery disease, kidney disease, seizures are associated with Attention deficit hyperactivity disorder medicines.
Impact of COVID-19 on the Global ADHD Therapeutics Market
The COVID-19 has had a lot of negative impact on people suffering from attention-deficit hyperactivity disorder. The main reason for the effect is vulnerability to the distress caused by the pandemic and physical distancing measures. Due to these factors, the patient can showcase an increase in behavioral problems. The increase in the issues will boost the sale of ADHD therapeutics, and the panic buying by consumers has finished the stock of the current batch of medicines and forced them to make a new batch. Hospital visits of all non-essential medical conditions have been postponed, causing individuals with ADHD solely reliant on medicines.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type, Production Technologies and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global attention deficit hyperactivity disorder therapeutics market has been segmented and sub-segmented based on the Type, Production Technologies, and Region.
ADHD Therapeutics Market - Treatment by Medication:
Based on the medication types, stimulants are expected to emerge as the drugs of choice, both among physicians and patients worldwide. Amphetamine is also to gain popularity over the forecast period.
Stimulants to lead the market and are expected to grow at a promising rate from 2020 to 2025. Around 70-80% of children who have ADHD use stimulants as medication to treat the disease. Stimulants are further classified into amphetamines, Methylphenidate, Dextroamphetamine, Dexmethylphenidate. These stimulants help in the cure for ADHD. These are drugs acts as a stimulant for the central nervous system. The most common stimulant used is Concerta (methylphenidate), Dexedrine (amphetamine), and Evekeo (amphetamine).
Nonstimulants accounted for the second market share in 2019, and with the rise in cases, the growth expected is positive in the future. Non stimulants are further divided into Atomoxetine, Bupropion, and Guanfacine. These drugs are used to treat ADHD are taken with stimulants as well as alone. Atomoxetine is recommended for patients above six years.
ADHD Therapeutics Market - Treatment by Psychotherapy:
Based on the psychotherapy treatment type, the Behavior therapy segment is the most commonly used method for ADHD treatment. It is an effective treatment that can help children improve their self-esteem, behavior, and self-control. It is mostly useful along with the stimulant medication going on, and with time we can see reduce in the dosage of medication.
Interpersonal psychotherapy is a time-limited and focused approach to treat mood disorders. Its popularity is increasing day by day, and is very effective in treating ADHD.
Family therapy is very effective in treating ADHD, and its popularity is increasing day by day.
ADHD Therapeutics Market - Treatment by Education or Training:
Parent Management Training is most popular among others. It is incredibly efficient in treating ADHD, and the rising awareness about its effectiveness will further drive its market.
Social skills training by schools and experts are also very effective in treating ADHD. Schools based intervention method is also being used more to treat ADHD, and with the rising cases, the method will increase at a fast pace.
ADHD Therapeutics Market – By Region:
Geographically, North America commanded the highest share of 36.0% of the global ADHD therapeutics market in 2019. In contrast, Asia-Pacific is estimated to grow at the highest CAGR of 12.30% during the forecast period 2019 to 2024.
North America leads the ADHD therapeutics market with the largest market share. The growing rate of patients in Attention deficit hyperactivity disorder and high healthcare expenditure is responsible for regional market growth. It is the reason behind the large revenue pocket of the local market in the U.S. The region would hold its leading position in the global Attention deficit hyperactivity disorder therapeutics market in the forecast period.
THE European ADHD market holds the second-most position along with emerging technology and digital medicines. The affluent medical device market and growing healthcare expenditure are responsible for the growth of the market.
The Asia Pacific region is also increasing in the ADHD therapeutics market. The factors responsible for the growth of the market are the unmet needs and sizeable patient population, even the availability of lower-cost drugs for the ADHD treatment. Moreover, improving the economy in the region is acting as a key to the success of pushing up the regional market and boosting the healthcare sector. Private organizations and the increased funding from the population are responsible for the growth of the regional market. The explosion of healthcare insurance in many countries like Malaysia, Thailand, and Vietnam are expected to drive the ADHD market in the Asia Pacific region. Also, the availability of the new treatments and the technology affect the growing demand and propel the growth of the regional ADHD therapeutics market.
PROMISING COMPANIES OPERATING IN THE MARKET
Some of the key market players dominating the global ADHD therapeutics market profiled in the report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Treatment By Medication
5.2.1 Introduction
5.2.2 Stimulants
5.2.2.1 Introduction
5.2.2.2 Amphetamines
5.2.2.3 Methylphenidate
5.2.2.4 Dextroamphetamine
5.2.2.5 Dexmethylphenidate
5.2.3 Non-Stimulants
5.2.3.1 Introduction
5.2.3.2 Atomoxetine
5.2.3.3 Bupropion
5.2.3.4 Guanfacine
5.3 Treatment By Psychotherapy
5.3.1 Introduction
5.3.2 Behavior Therapy
5.3.3 Cognitive Behavioral Therapy
5.3.4 Interpersonal Psychotherapy
5.3.5 Family Therapy
5.4 Treatment By Education or Training
5.3.1 Introduction
5.3.2 Parent Management Training
5.3.3 Social Skills Training
5.3.4 School-Based Interventions
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Shire plc (Ireland)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Neos Therapeutics, Inc. (U.S.)
8.3 Eli Lilly and Company (U.S.)
8.4 Pfizer Inc. (U.S.)
8.5 Alcobra Ltd. (Israel)
8.6 Supernus Pharmaceuticals, Inc. (U.S.)
8.7 Noven Pharmaceuticals, Inc. (U.S.)
8.8 Novartis AG (Switzerland)
8.9 Johnson & Johnson (U.S.)
8.10 Curemark, LLC., (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
